130 related articles for article (PubMed ID: 1676899)
1. Curdlan sulfate and HIV-1. I. In vitro inhibitory effects of curdlan sulfate on HIV-1 infection.
Aoki T; Kaneko Y; Stefanski MS; Nguyen T; Ting RC
AIDS Res Hum Retroviruses; 1991 Apr; 7(4):409-15. PubMed ID: 1676899
[TBL] [Abstract][Full Text] [Related]
2. Curdlan sulfate and HIV-1: II. In vitro long-term treatment of HIV-1 infection with curdlan sulfate.
Aoki T; Kaneko Y; Nguyen T; Stefanski MS; Ting RC; Manak MM
AIDS Res Hum Retroviruses; 1992 May; 8(5):605-12. PubMed ID: 1515213
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of the inhibitory effect of curdlan sulfate on HIV-1 infection in vitro.
Jagodzinski PP; Wiaderkiewicz R; Kurzawski G; Kloczewiak M; Nakashima H; Hyjek E; Yamamoto N; Uryu T; Kaneko Y; Posner MR
Virology; 1994 Aug; 202(2):735-45. PubMed ID: 7913276
[TBL] [Abstract][Full Text] [Related]
4. Role of the V2, V3, and CD4-binding domains of GP120 in curdlan sulfate neutralization sensitivity of HIV-1 during infection of T lymphocytes.
Jagodzinski PP; Wustner J; Kmieciak D; Wasik TJ; Fertala A; Sieron AL; Takahashi M; Tsuji T; Mimura T; Fung MS; Gorny MK; Kloczewiak M; Kaneko Y; Kozbor D
Virology; 1996 Dec; 226(2):217-27. PubMed ID: 8955041
[TBL] [Abstract][Full Text] [Related]
5. Curdlan sulfate (CRDS) in a 21-day intravenous tolerance study in human immunodeficiency virus (HIV) and cytomegalovirus (CMV) infected patients: indication of anti-CMV activity with low toxicity.
Gordon M; Deeks S; De Marzo C; Goodgame J; Guralnik M; Lang W; Mimura T; Pearce D; Kaneko Y
J Med; 1997; 28(1-2):108-28. PubMed ID: 9249617
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of curdlan sulfate--an HIV inhibitor. Tolerance, pharmacokinetics and effects on coagulation and on CD4 lymphocytes.
Gordon M; Guralnik M; Kaneko Y; Mimura T; Baker M; Lang W
J Med; 1994; 25(3-4):163-80. PubMed ID: 7996061
[TBL] [Abstract][Full Text] [Related]
7. Role of curdlan sulfate in the production of beta-chemokines and interleukin-16.
Naito T; Takeda-Hirokawa N; Kaneko H; Sekigawa I; Matsumoto T; Hashimoto H; Kaneko Y
Med Microbiol Immunol; 1998 Jun; 187(1):43-8. PubMed ID: 9749981
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of HIV-1 replication and infectivity by expression of a fusion protein, VPR-anti-integrase single-chain variable fragment (SFv): intravirion molecular therapies.
BouHamdan M; Kulkosky J; Duan LX; Pomerantz RJ
J Hum Virol; 2000; 3(1):6-15. PubMed ID: 10774802
[TBL] [Abstract][Full Text] [Related]
9. Further clinical studies of curdlan sulfate (CRDS)--an anti-HIV agent.
Gordon M; Guralnik M; Kaneko Y; Mimura T; Goodgame J; Lang W
J Med; 1995; 26(3-4):97-131. PubMed ID: 8558101
[TBL] [Abstract][Full Text] [Related]
10. Role of curdlan sulfate in the binding of HIV-1 gp120 to CD4 molecules and the production of gp120-mediated TNF-alpha.
Takeda-Hirokawa N; Neoh LP; Akimoto H; Kaneko H; Hishikawa T; Sekigawa I; Hashimoto H; Hirose S; Murakami T; Yamamoto N; Mimura T; Kaneko Y
Microbiol Immunol; 1997; 41(9):741-5. PubMed ID: 9343827
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of HIV infection by baicalin--a flavonoid compound purified from Chinese herbal medicine.
Li BQ; Fu T; Yan YD; Baylor NW; Ruscetti FW; Kung HF
Cell Mol Biol Res; 1993; 39(2):119-24. PubMed ID: 7693133
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of HIV-1 infectivity with curdlan sulfate in vitro.
Kaneko Y; Yoshida O; Nakagawa R; Yoshida T; Date M; Ogihara S; Shioya S; Matsuzawa Y; Nagashima N; Irie Y
Biochem Pharmacol; 1990 Feb; 39(4):793-7. PubMed ID: 1968342
[No Abstract] [Full Text] [Related]
13. HIV-1 gag proteins in virions and in infected cell fractions.
Sharova NK; Grigor'ev VB; Bukrinskaya AG
Biomed Sci; 1991; 2(3):279-84. PubMed ID: 1751761
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of HIV-1 replication in H9 cells by nystatin-A compared with other antiviral agents.
Selvam MP; Blay RA; Geyer S; Buck SM; Pollock L; Mayner RE; Epstein JS
AIDS Res Hum Retroviruses; 1993 May; 9(5):475-81. PubMed ID: 7686387
[TBL] [Abstract][Full Text] [Related]
15. Kinetics of infected cell appearance as a determinant of number of human immunodeficiency virus-1 infectious units.
Cory JM; Ohlsson-Wilhelm BM; Steck ME; Smithgall MD; Rozday V; Eyster ME; Rapp F
AIDS Res Hum Retroviruses; 1989 Feb; 5(1):97-106. PubMed ID: 2497763
[TBL] [Abstract][Full Text] [Related]
16. Syncytium induction by fresh HIV isolates: quantitative analysis using a transactivation beta-gal assay.
Emilie D; Maillot MC; Bonnerot C; Devergne O; Delfraissy JF; Nicolas JF; Galanaud P
AIDS; 1990 Aug; 4(8):791-7. PubMed ID: 1979746
[TBL] [Abstract][Full Text] [Related]
17. Sulfated polysaccharide, curdlan sulfate, efficiently prevents entry/fusion and restricts antibody-dependent enhancement of dengue virus infection in vitro: a possible candidate for clinical application.
Ichiyama K; Gopala Reddy SB; Zhang LF; Chin WX; Muschin T; Heinig L; Suzuki Y; Nanjundappa H; Yoshinaka Y; Ryo A; Nomura N; Ooi EE; Vasudevan SG; Yoshida T; Yamamoto N
PLoS Negl Trop Dis; 2013; 7(4):e2188. PubMed ID: 23658845
[TBL] [Abstract][Full Text] [Related]
18. CD8+ T cells inhibit HIV replication in naturally infected CD4+ T cells. Evidence for a soluble inhibitor.
Brinchmann JE; Gaudernack G; Vartdal F
J Immunol; 1990 Apr; 144(8):2961-6. PubMed ID: 1969879
[TBL] [Abstract][Full Text] [Related]
19. MAP 30: a new inhibitor of HIV-1 infection and replication.
Lee-Huang S; Huang PL; Nara PL; Chen HC; Kung HF; Huang P; Huang HI; Huang PL
FEBS Lett; 1990 Oct; 272(1-2):12-8. PubMed ID: 1699801
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 infection of human CD4+ T cells in vitro. Differential induction of apoptosis in these cells.
Martin SJ; Matear PM; Vyakarnam A
J Immunol; 1994 Jan; 152(1):330-42. PubMed ID: 7902858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
